BI 3034701

BI 3034701, also written BI3034701, is an experimental peptide being studied for weight loss. Researchers want to know whether acting on three signals in the body helps people lose weight and how well they handle the treatment.

How Does BI 3034701 Work?

Ever notice how your hunger eases as you eat? That happens in part because your brain picks up signals that help control your appetite. One place those signals can land is a receptor called NPY2. When it switches on, you may feel less hungry.

The peptide is designed to activate NPY2 and two other receptors called GLP-1 and GIP. That’s why researchers call it a triple agonist. Retatrutide also acts on GLP-1 and GIP, but its third target is the glucagon receptor instead of NPY2.

How Much Weight Did People Lose?

Gubra called the early results “encouraging.” Its Phase 1 summary gives no figure for how much weight people lost on average, either in pounds or as a percentage of their starting weight.

The company also described safety and how well people tolerated the peptide as “favorable.” Its summary doesn’t say which side effects people had or how often they occurred. Gubra’s research summary

What Is the Phase 2 Trial Testing?

The trial enrolled 344 adults and assigned them by chance to seven groups. Six groups receive the peptide, each at a different dose. The seventh gets a placebo, an injection with no active drug. After 42 weeks, researchers will compare the groups to see how much weight people lost at each dose.

Researchers expect to take the last weight measurement for that comparison by June 26, 2027. They expect to finish the study by July 10, 2027. Both dates are estimates. The trial record gives no date for when the public can see the results.

Is BI 3034701 Available Yet?

You can’t get it by prescription. The Phase 2 trial is still running, but enrollment has closed. You can follow the trial record for updates on BI 3034701.